Posted inGeneral Surgery news Oncology
EsoTIME: Precision Survival Prediction Replaces Traditional Staging for Resected Esophageal and Gastroesophageal Junction Cancers
The EsoTIME tool provides a validated, high-accuracy method for predicting 3-year survival in patients with resected esophageal and gastroesophageal junction cancers, utilizing population-based data to improve personalized clinical decision-making.